Anti-BRCA2 antibody (ab123491)
Key features and details
- Rabbit polyclonal to BRCA2
- Suitable for: WB, IP
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-BRCA2 antibody
See all BRCA2 primary antibodies -
Description
Rabbit polyclonal to BRCA2 -
Host species
Rabbit -
Tested applications
Suitable for: WB, IPmore details -
Species reactivity
Reacts with: Human
Predicted to work with: Chimpanzee, Rhesus monkey, Gorilla, Orangutan -
Immunogen
Synthetic peptide, corresponding to a region within amino acids 450-500 of Human BRCA2 using the numbering given in entry NP_000050.1.
-
Positive control
- Whole cell lysate from 293T, HeLa and Jurkat cells
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
Storage buffer
pH: 7
Preservative: 0.09% Sodium azide
Constituent: 99% Tris citrate/phosphate
pH 7 to 8 -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Positive Controls
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab123491 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB | (2) |
1/2000 - 1/10000. Predicted molecular weight: 384 kDa.
|
IP |
Use at 2-10 µg/mg of lysate.
|
Notes |
---|
WB
1/2000 - 1/10000. Predicted molecular weight: 384 kDa. |
IP
Use at 2-10 µg/mg of lysate. |
Target
-
Function
Involved in double-strand break repair and/or homologous recombination. Binds RAD51 and potentiates recombinational DNA repair by promoting assembly of RAD51 onto single-stranded DNA (ssDNA). Acts by targeting RAD51 to ssDNA over double-stranded DNA, enabling RAD51 to displace replication protein-A (RPA) from ssDNA and stabilizing RAD51-ssDNA filaments by blocking ATP hydrolysis. May participate in S phase checkpoint activation. Binds selectively to ssDNA, and to ssDNA in tailed duplexes and replication fork structures. -
Tissue specificity
Highest levels of expression in breast and thymus, with slightly lower levels in lung, ovary and spleen. -
Involvement in disease
Defects in BRCA2 are a cause of susceptibility to breast cancer (BC) [MIM:114480]. A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.
Defects in BRCA2 are the cause of pancreatic cancer type 2 (PNCA2) [MIM:613347]. It is a malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.
Defects in BRCA2 are a cause of susceptibility to breast-ovarian cancer familial type 2 (BROVCA2) [MIM:612555]. A condition associated with familial predisposition to cancer of the breast and ovaries. Characteristic features in affected families are an early age of onset of breast cancer (often before age 50), increased chance of bilateral cancers (cancer that develop in both breasts, or both ovaries, independently), frequent occurrence of breast cancer among men, increased incidence of tumors of other specific organs, such as the prostate.
Defects in BRCA2 are the cause of Fanconi anemia complementation group D type 1 (FANCD1) [MIM:605724]. It is a disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair.
Defects in BRCA2 are a cause of glioma type 3 (GLM3) [MIM:613029]. Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. -
Sequence similarities
Contains 8 BRCA2 repeats. -
Post-translational
modificationsPhosphorylated by ATM upon irradiation-induced DNA damage.
Ubiquitinated in the absence of DNA damage; this does not lead to proteasomal degradation. In contrast, ubiquitination in response to DNA damage leads to proteasomal degradation. - Information by UniProt
-
Database links
- Entrez Gene: 675 Human
- Omim: 600185 Human
- SwissProt: P51587 Human
- Unigene: 34012 Human
-
Alternative names
- BRCA 2 antibody
- BRCA1/BRCA2 containing complex subunit 2 antibody
- Brca2 antibody
see all
Images
-
All lanes : Anti-BRCA2 antibody (ab123491) at 0.1 µg/ml
Lane 1 : 293T whole cell lysate at 50 µg
Lane 2 : 293T whole cell lysate at 15 µg
Lane 3 : 293T whole cell lysate at 5 µg
Lane 5 : HeLa whole cell lysate at 50 µg
Lane 6 : HeLa whole cell lysate at 15 µg
Predicted band size: 384 kDa
Exposure time: 30 seconds -
Detection of Human BRCA2 by Immunoprecipitation from HeLa whole cell lysate (1 mg for IP, 20% of IP loaded), using ab123491 at 6 µg/mg lysate.
Subsequent Western blot detection used ab123491 at 1 µg/ml.
Detection: Chemiluminescence with an exposure time of 10 seconds. -
All lanes : Anti-BRCA2 antibody (ab123491) at 0.1 µg/ml
Lane 1 : Whole cell lysate from HeLa at 50 µg/ml
Lane 2 : Whole cell lysate from HeLa at 15 µg/ml
Lane 3 : Whole cell lysate from 293T at 50 µg/ml
Lane 4 : Whole cell lysate from Jurkat at 50 µg/ml
Developed using the ECL technique.
Predicted band size: 384 kDa
Exposure time: 10 minutes
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (13)
ab123491 has been referenced in 13 publications.
- Goldsmith J et al. Ribosome profiling reveals a functional role for autophagy in mRNA translational control. Commun Biol 3:388 (2020). PubMed: 32681145
- Ji W et al. Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors. Biochem Biophys Res Commun 522:121-126 (2020). PubMed: 31753490
- Shang Y et al. MEIOK21: a new component of meiotic recombination bridges required for spermatogenesis. Nucleic Acids Res N/A:N/A (2020). PubMed: 32463460
- Chen HD et al. Novel mutations in BRCA2 intron 11 and overexpression of COX-2 and BIRC3 mediate cellular resistance to PARP inhibitors. Am J Cancer Res 10:2813-2831 (2020). PubMed: 33042619
- Le HP et al. DSS1 and ssDNA regulate oligomerization of BRCA2. Nucleic Acids Res 48:7818-7833 (2020). PubMed: 32609828